/ /

  • linkedin
  • Increase Font
  • Sharebar

    Patients report positive results from ocriplasmin for vitreomacular adhesion

    Self-reported assessments of improvement hold just as much value as clinical changes


    Take-home message: Improvement in patients’ assessment of visual function was reported after treatment with intravitreal ocriplasmin for vitreomacular adhesion.



    Los Angeles—Patients with symptomatic vitreomacular adhesion report that a new injectable drug, ocriplasmin (Jetrea, ThromboGenics), improves their vision.

    The patient reported results were part of two ancillary analyses from a multinational clinical trial that showed positive clinical results.

    “The key message is that ocriplasmin improves an individual’s assessment of their quality of life and vision-related function,” said lead author Rohit Varma, MD, Grace and Emery Beardsley Professor and Chairman, Department of Ophthalmology, University of Southern California (USC) Keck School of Medicine, and director, USC Eye Institute, Los Angeles.

    “What we found was clinically meaningful improvement in patient’s self-reported ability to perform vision-related tasks,” Dr. Varma added.

    Did you know these 7 men were ophthalmologists?

    The study was published earlier this year (Varma R et al. Improvement in patient-reported visual function after ocriplasmin for vitreomacular adhesion. JAMA Ophthalmol. Published online June 11, 2015).

    The patient-reported outcomes were collected as part of the larger Microplasmin for Intravitreous Injection-Traction Release with Surgical Treatment (MIVI-TRUST) trials. The primary results of two multicenter trials conducted in Europe and the United states were published in 2012.

    The clinical results showed that the enzymatic vitreolysis with ocriplasmin resolved vitreomacular traction and closed macular holes in significantly more patients compared with placebo. The drug was approved by the FDA in 2012 and is marketed as Jetrea by ThromboGenics, which sponsored both the clinical trials and the patient-reported outcomes analyses.

    Next: "It is critically important that we know how the patients feel"

    Fred Gebhart
    The author is a correspondent for Urology Times, a sister publication.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results